Oxford Stops TroVax Trial

Oxford BioMedica is halting new vaccinations in its Phase III study of the renal cancer vaccine TroVax following the recommendation of its independent data safety monitoring board (DSMB).

After its fourth interim review of the study, the DSMB determined the vaccine would not meet its primary efficacy endpoint, Oxford said. It is developing the vaccine with sanofi-aventis and will continue monitoring previously vaccinated patients.

While the current study may not support registration of TroVax for renal cancer, it may demonstrate a survival advantage and its results, coupled with those of another trial, may form part of a regulatory submission, Oxford said.